On October 3, 2023 PharmaEssentia Corporation, (TPEx:6446), a global biopharmaceutical innovator headquartered in Taiwan leveraging deep expertise and proven scientific principles to deliver new biologics in hematology and oncology, reported that it has entered into a license agreement with WuXi Biologics Ireland Limited to obtain the global exclusive rights to research, develop, manufacture and commercialize a myeloid immune checkpoint antibody candidate (Press release, PharmaEssentia, OCT 3, 2023, View Source [SID1234635619]). PharmaEssentia will take over responsibility for the subsequent preclinical and clinical development efforts.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"We are excited to expand our pipeline, which reflects our dedication to growing our research capabilities and delivering transformative healthcare solutions," said Ko-Chung Lin, Ph.D., Founder and Chief Executive Officer, PharmaEssentia. "Entering into this agreement with WuXi Biologics perfectly aligns with our commitment to accelerate priority development programs across oncology, hematology and immunology. We’re poised to pioneer breakthrough therapies and bring renewed hope to patients worldwide."
"PharmaEssentia’s mission is to create best-in-class or first-in-class therapies by expanding our expertise to new drug modalities where we can have the greatest impact on patient lives," said Lih-Ling Lin, Ph.D., Chief Scientific Officer, PharmaEssentia. "As one of the first programs that will be advanced by our global research and business development team, we are eager to apply our deep biopharmaceutical capabilities to better understand the clinical potential of this novel approach. We are committed to working urgently to advance this candidate, which has the potential to apply a new scientific breakthrough to create a treatment that helps alleviate the incredible medical burdens faced by patients living with solid tumors."
As part of the agreement, PharmaEssentia will pay license fees to WuXi Biologics, including an upfront payment upon signing, future research, development, regulatory and sales milestones payments, and sales royalties.